Chimeric antigen receptor T cell therapy - Parasol Biotech
Alternative Names: Anti-guanylate cyclase 2C CAR T cells; GUCY2C-targeting CAR T cell therapy - Parasol Biotech; GUCY2C-targeting CAR T cellsLatest Information Update: 31 Aug 2023
At a glance
- Originator Parasol Biotech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Colorectal cancer